Iovance Advances Another TIL Therapy in Melanoma and NSCLC
The first patient dosed with IOV-4001 has completed the safety observation period.
Anti-HIV CAR-T Therapy Trial Doses First Patient
Preclinical research showed the therapy was able to reduce cellular HIV infection by up to 99% in an in vitro model and more than 97% in a mouse model.
Val-Rox up for Review in Hemophilia A 2 Years After Initial BLA Submission
The PDUFA target date is set for March 31, 2023.
Deyaa Adib, MD, on Optimizing Manufacturing of Solid Tumor Cell Therapies
The chief medical officer of Triumvira Immunologics discussed the company’s future plans.
Around the Helix: Cell and Gene Therapy Company Updates – October 12, 2022
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Patients With Fabry Disease Withdrawn From ERT After Isaralgagene Civaparvovec Treatment
All 5 patients on ERT at study start have since been able to withdraw after gene therapy treatment.
Janssen’s Gene Therapies Show Promise in Retinitis Pigmentosa, Geographic Atrophy
Both botaretigene sparoparvovec and JNJ-81201887 were well-tolerated in treated patients, according to data from the 2022 AAO meeting.
Roberto Giugliani, MD, PhD, on Advantages of Gene Therapy in MPS Type 2
The professor of genetics at Federal University of Rio Grande do Sul discussed how RGX-121 has the potential to change the treatment landscape of MPSII.
TCR-T Therapy Yields Clinical Responses Across Tumor Types
ORR was 80% in the first cohort of phase 1b at the recommended phase 2 dose.
Baseline Neurofilament Light Levels Predict Neurotoxicity With CAR T-Cell Therapy
A retrospective study measured correlations of ICANS and NfL in patients with a history of diffuse large B-cell lymphoma.
Clive Svendsen, PhD, on Astrocyte Progenitor Cell Therapy in ALS
The director of the Regenerative Medicine Institute at Cedars Sinai discussed results from a phase 1/2a study of CNS10-NPC-GDNF.
Achieving Remission in Lupus With CAR T Therapy
Teodora Staeva, PhD, chief scientific officer, Lupus Research Alliance, discussed the potential of the approach in patients with SLE.
TIL Therapy to be Assessed in Relapsed/Refractory Melanoma
Lyell will soon initiate a phase 1 trial of LYL845 with initial data expected in 2024.
CGTLive’s Weekly Rewind – October 7, 2022
Review top news and interview highlights from the week ending October 7, 2022.
Samir Parekh, MD, on Investigating Treatment Options for Relapsed Myeloma
The director of translational research in myeloma at the Tisch Cancer Institute discussed investigating sequential T cell redirection therapies.
New, Multicenter Trial of MB-106 Doses First Patient
Interim data from an ongoing study demonstrate continuing efficacy in B-NHL, CLL, and FL.
CardiAMP Cell Therapy Yields 100% Response Rate in Heart Failure
The new, 2-year data is from a roll-in cohort of 10 patients presented at the HFSA 2022 meeting.
Treating Autoimmune Diseases With Smarter Cell Therapies
Karen Walker, chief technology officer, Kyverna Therapeutics, discussed the company’s CAR T-cell and regulatory T-cell technologies.
Around the Helix: Cell and Gene Therapy Company Updates – October 5, 2022
CAR T Therapy Yields Remission in Systemic Lupus Erythematosus
Five patients with lupus treated with anti-CD19 CAR T-cell therapy are now in remission.
B-NHL Cell Therapy Cleared for Trials
Oncternal will soon initiate a phase 1/2 dose-escalation study of ONCT-808.
Christine Coughlin, MD, PhD, on TRACK-NK Technology in Non-Small Cell Lung Cancer
The chief executive officer of Cytoimmune discussed the company’s technology platforms and programs.
Gene Therapy Yields Improvements in Danon Disease
Rocket Pharma presented updated data from adult and pediatric patients at the 2022 HFSA meeting.
Sid Kerkar, MD, on Developing CAR T Therapies Without Lymphodepletion Chemotherapy
The vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.
Solid Bio Adds Friedreich Ataxia to Pipeline With Aavanti Acquisition
Solid has also pivoted from developing SGT-001 to SGT-003 for treating Duchene muscular dystrophy.
Wet AMD Gene Therapy Reduces Anti-VEGF Treatment Burden
Participants in the AAVIATE trial had up to an 85% decrease in treatment burden 6 months after treatment with RGX-314.
Advancing Neonatal Cell Therapy Research
Newborn Cell Therapies Group at Monash University has received a $50,000 grant from Lions Cord Blood foundation.
Omidubicel Improves Survival in Hematologic Malignancies With HSCT
Disease-free survival was 56% in 105 participants over 3 years.
CGTLive’s Weekly Rewind – September 30, 2022
Review top news and interview highlights from the week ending September 30, 2022.
Modified Immune Cell Therapy Induces Kidney-Donor-Specific Immunosuppression
Patients treated with the highest dose of MIC-Lx had lymphocyte reactivity against third-party cells but not stimulatory donor blood cells.
